Importantly, our work revealed a distinct metabolic rewiring mechanism harnessed by a different subset of melanoma cells, namely the CD36+ SMCs, to mediate their tolerance to MAPK-targeted therapies (Figures 4 and 5). Here, CD36 is linked to melanoma.